Breast Cancer Information

Early Breast Cancer Detection


Most women are familiar with mammography as our "gold standard" for breast cancer screening. However, there are additional tools available that women can add to their arsenal.

One of the most effective tools in breast cancer screening is breast self-exam (BSE). However, BSE works best when women are appropriately trained in the procedure, and then followed-up with annual clinical breast exams (CBE) from their physicians. In a 2000 University of Toronto study, approximately 20,000 women were screened for breast cancer with BSE and annual CBE, and 20,000 were screened with BSE and mammograms. After more than 10 years, the BSE and annual CBE reported 610 cases of invasive breast cancer, and 105 deaths. In the BSE and mammogram group, there were 622 cases of invasive breast cancer and 107 deaths. Without question, the first line of defense against breast cancer begins with diligent BSE.

Other tools that are available to women include the AMAS (anti-malignan antibody screen) test and the NMP Nuclear matrix protein) test. Both these are blood tests that measure a certain protein in the blood that may indicate cancer. The AMAS test has been around for several years while the NMP test has not been available until only recently. Clinical trials continue in this area.

One additional tool that may detect an issue early is digital infrared thermal imaging or DITI. In 1982, the FDA approved thermography as an adjunctive tool for breast cancer screening. DITI measures heat emitted from the body and is accurate to 1/100th of a degree. DITI examines physiology, NOT structure. It is in this capacity that DITI can monitor breast HEALTH over time and alert a patient or physician to a developing problem; possibly before a lump can be seen on X-ray or palpated clinically. There are no test limitations such as breast density. DITI is a non-invasive test that does not emit radiation.

The unique characteristics of cancer allow DITI to detect breast cancer at an earlier stage of growth. As cancer is developing, it builds its own blood supply which is then reflected as increased heat in that particular region of the breast. DITI has a specificity of 83%; which reflects a problem in its early stages of development not late-stage cancer as in mammography. An abnormal thermogram carries a 10-times greater risk for cancer and a persistently abnormal thermogram carries a 22-times greater risk for cancer.

Clinical research studies continue to support thermography's role as an adjunctive tool in breast cancer screening and the ONLY tool that measures breast health over time. There are now more than 800 publications on over 300,000 women in clinical trials. A recent finding published in the American Journal of Radiology in 2003 showed that thermography has 99% sensitivity in identifying breast cancer with single examinations and limited views. Scientists concluded that a negative thermogram is powerful evidence that cancer is not present.

Thermographic screening is not covered by most insurance companies but is surprisingly affordable for most people. For more information or to find a certified clinic in your area, go to www.proactivehealthonline.com.

Brenda Witt is co-owner of Proactive Health Solutions in Southern California. She is an American College of Clinical Thermology (ACCT) certified thermographer in the Orange County area.


MORE RESOURCES:

Play to raise breast cancer awareness
Gulf Daily News, Bahrain - 13 hours ago
By REBECCA TORR A BAHRAINI play that highlights the suffering of breast cancer patients will be staged at the Bahrain National Museum's Cultural Hall this ...


BBC News

Breast cancer: More conflicting exam info for women to consider
Aurora Beacon News, IL - 2 hours ago
It was the spring of 2006 and the Montgomery woman was only 31, too young, she thought, for breast cancer. When the pain continued and Chivari felt a lump, ...
Area experts champion breast cancer self-exams Corvallis Gazette Times
Breast cancer self-exams 'do more harm than good' Scotsman
Breast self-exams do not cut breast cancer deaths Reuters UK
Science Daily (press release) - phillyBurbs.com
all 201 news articles


Major Leaguers join forces in fight against breast cancer
Newnan Times-Herald, GA - 8 hours ago
The group of 22 Coweta area women, are currently collecting funds to participate in the Atlanta Breast Cancer 3-Day, a 60-mile walk spanning three days in ...


Digital mammograms focus of grants from breast cancer group
TheChronicleHerald.ca, Canada - Jul 19, 2008
By JOHN GILLIS Health Reporter The Canadian Breast Cancer Foundation helped support the shift to digital mammography with grants awarded this week. ...
Breast cancer mortality in BC lowest in Canada Vancouver Sun
Breast cancer research funded; Peterborough Examiner
NB breast cancer research gets funds Times and Transcript
Telegraph-Journal
all 6 news articles


Breast cancer screening available
The Newark Advocate, OH - 23 minutes ago
NEWARK -- On July 29, the Licking County Health Department's SASS for Breast Cancer Program is sponsoring free screening mammograms for eligible women. ...


Surgeon to test breast cancer vaccine
Allentown Morning Call, PA - 2 hours ago
Most breast cancer vaccine studies nationwide focus on women with advanced disease, but Riley's will look at women in the early stages of the disease. ...


Serum Metastasin mRNA is an Important Survival Predictor in Breast ...
RedOrbit, TX - 2 hours ago
In total, 50% of the breast cancer patients, 86.7% of the benign group and 53.3% of the healthy controls were premenopausal. The benign breast lesions ...


Breast cancer not linked to coffee, tea
Nashua Telegraph, NH - 7 hours ago
The question: Does drinking coffee or tea affect the likelihood that a woman will develop breast cancer? The latest: This study analyzed data on 85987 ...


Biocon launches nano-based breast cancer drug
MyNews.in, India - Jul 18, 2008
Stating that every year more than one lakh women were diagnosed with breast cancer and mortality rate was about 45000, she said the growth rate of this ...


Biocon, US firm launch breast cancer drug in India
Business Standard, India - Jul 18, 2008
Bio-tech major Biocon and US-based Abraxis Inc today announced the launch of Abraxane in the country for the treatment of breast cancer after the failure if ...

Breast-Cancer - Google News

home | site map
© 2006